| 摘要 |
<p>The invention relates to lipid metabolism, and to the uptake of lipoproteins via the Low-Density Lipoprotein receptor (LDLR), the Very Low Density Lipoprotein Receptor (VLDLR) and/or the Low density lipoprotein receptor-related protein 8 (apoER2) receptor. The invention provides novel biological targets associated with the degradation of these receptors, and pharmaceutical compositions, medicaments and methods of treatment for use in preventing, ameliorating or treating symptoms of hypercholesterolaemia and cardiovascular disease.</p> |
